Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
EBITDA Margin Of 33% Not Sustainable, Krka Underlines
Demand Driven By Pandemic Has Boosted Krka’s Bottom Line
Nov 23 2020
•
By
Dean Rudge
"Margins will gradually return towards the top end of target range," Krka has made clear. • Source: Shutterstock
More from Earnings
More from Business